Chris J. Packard

Glasgow, SCT, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 112 publications

Angiopoietin-like protein 3 complete and partial deficiency markedly accelerates apolipoprotein B48 and B100 metabolism in triglyceride-rich lipoproteins in humans.

Angiopoietin-like protein 3 complete and partial deficiency markedly accelerates apolipoprotein B48 and B100 metabolism in triglyceride-rich lipoproteins in humans.

Journal: Journal of internal medicine

Published: June 11, 2026

Apolipoprotein B-containing lipoproteins: distinct roles in atherosclerosis revealed by plasma proteomic profiling.

Apolipoprotein B-containing lipoproteins: distinct roles in atherosclerosis revealed by plasma proteomic profiling.

Journal: European heart journal

Published: February 28, 2026

Apolipoprotein C-III: Risk-factor, Regulator of Triglyceride-rich Lipoprotein Metabolism and Therapeutic Target.

Apolipoprotein C-III: Risk-factor, Regulator of Triglyceride-rich Lipoprotein Metabolism and Therapeutic Target.

Journal: Current atherosclerosis reports

Published: January 07, 2026

Clinical relevance of per-particle atherogenicity of triglyceride-rich lipoproteins, Lp(a) and LDL for cardiovascular risk.

Clinical relevance of per-particle atherogenicity of triglyceride-rich lipoproteins, Lp(a) and LDL for cardiovascular risk.

Journal: Pharmacology & therapeutics

Published: December 15, 2025

'Genetic modelling of triglyceride-rich lipoprotein/remnant lowering mimics APOC3-silencing and predicts clinically relevant coronary heart disease event reductions': author's response.

'Genetic modelling of triglyceride-rich lipoprotein/remnant lowering mimics APOC3-silencing and predicts clinically relevant coronary heart disease event reductions': author's response.

Journal: European journal of preventive cardiology

Published: October 24, 2025

Triglyceride-rich lipoproteins, remnants and atherosclerotic cardiovascular disease: What we know and what we need to know.

Triglyceride-rich lipoproteins, remnants and atherosclerotic cardiovascular disease: What we know and what we need to know.

Journal: Atherosclerosis

Published: July 27, 2025

Genetic modelling of triglyceride-rich lipoprotein/remnant lowering mimics APOC3-silencing and predicts clinically relevant coronary heart disease event reductions.

Genetic modelling of triglyceride-rich lipoprotein/remnant lowering mimics APOC3-silencing and predicts clinically relevant coronary heart disease event reductions.

Journal: European journal of preventive cardiology

Published: July 08, 2025

Risk-weighted apoB: a novel summary metric outperforming traditional lipid biomarkers in predicting coronary heart disease.

Risk-weighted apoB: a novel summary metric outperforming traditional lipid biomarkers in predicting coronary heart disease.

Journal: European heart journal

Published: May 21, 2025

Editorial: The Brussels International Declaration on Lp(a) Testing And Management-A call to action.

Editorial: The Brussels International Declaration on Lp(a) Testing And Management-A call to action.

Journal: Atherosclerosis

Published: April 24, 2025

Great debate: Plasma triglycerides are an important causal factor and therapeutic target for atherosclerotic cardiovascular disease.

Great debate: Plasma triglycerides are an important causal factor and therapeutic target for atherosclerotic cardiovascular disease.

Journal: European heart journal

Published: April 11, 2025

Redefining the association of triglycerides with all-cause and Cardiovascular Disease Mortality in the Chinese population: a nationwide, population-based, prospective cohort study of 3.8 million Chinese adults.

Redefining the association of triglycerides with all-cause and Cardiovascular Disease Mortality in the Chinese population: a nationwide, population-based, prospective cohort study of 3.8 million Chinese adults.

Journal: The Lancet regional health. Western Pacific

Published: January 30, 2025

Concept and practice in the use of high-dose eicosapentaenoic acid for cardiovascular disease prevention in hypertriglyceridaemia.

Concept and practice in the use of high-dose eicosapentaenoic acid for cardiovascular disease prevention in hypertriglyceridaemia.

Journal: Heart (British Cardiac Society)

Published: January 18, 2025

Showing 1-12 of 112

Last Updated: 09/26/2026